prikaz prve stranice dokumenta Hibridna jednofotonska emisijska tomografija/kompjutorizirana tomografija (SPECT/CT) somatostatinskih receptora u dijagnostici neuroendokrinih tumora
  Download
PDF 2.8 MB
Scientific paper - Original scientific paper
Hibridna jednofotonska emisijska tomografija/kompjutorizirana tomografija (SPECT/CT) somatostatinskih receptora u dijagnostici neuroendokrinih tumora
Medicina Fluminensis, 57 (2021), 1; 73-80. https://doi.org/10.21860/medflum2021_365323
Maršić, Matej; Klarica Gembić, Tihana; Girotto, Neva; Pribanić, Ivan; Bogović Crnčić, Tatjana; Grbac-Ivanković, Svjetlana

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Maršić, M., Klarica Gembić, T., Girotto, N., Pribanić, I., Bogović Crnčić, T. & Grbac Ivanković, S. (2021). Hibridna jednofotonska emisijska tomografija/kompjutorizirana tomografija (SPECT/CT) somatostatinskih receptora u dijagnostici neuroendokrinih tumora. Medicina Fluminensis, 57. (1), 73-80. doi: 10.21860/medflum2021_365323

Maršić, Matej, et al. "Hibridna jednofotonska emisijska tomografija/kompjutorizirana tomografija (SPECT/CT) somatostatinskih receptora u dijagnostici neuroendokrinih tumora." Medicina Fluminensis, vol. 57, no. 1, 2021, pp. 73-80. https://doi.org/10.21860/medflum2021_365323

Maršić, Matej, Tihana Klarica Gembić, Neva Girotto, Ivan Pribanić, Tatjana Bogović Crnčić and Svjetlana Grbac Ivanković. "Hibridna jednofotonska emisijska tomografija/kompjutorizirana tomografija (SPECT/CT) somatostatinskih receptora u dijagnostici neuroendokrinih tumora." Medicina Fluminensis 57, no. 1 (2021): 73-80. https://doi.org/10.21860/medflum2021_365323

Maršić, M., et al. (2021) 'Hibridna jednofotonska emisijska tomografija/kompjutorizirana tomografija (SPECT/CT) somatostatinskih receptora u dijagnostici neuroendokrinih tumora', Medicina Fluminensis, 57(1), pp. 73-80. doi: 10.21860/medflum2021_365323

Maršić M, Klarica Gembić T, Girotto N, Pribanić I, Bogović Crnčić T, Grbac Ivanković S. Hibridna jednofotonska emisijska tomografija/kompjutorizirana tomografija (SPECT/CT) somatostatinskih receptora u dijagnostici neuroendokrinih tumora. Medicina Fluminensis [Internet]. 2021 March 01 [cited 2024 December 26];57(1):73-80. doi: 10.21860/medflum2021_365323

M. Maršić, T. Klarica Gembić, N. Girotto, I. Pribanić, T. Bogović Crnčić and S. Grbac Ivanković, "Hibridna jednofotonska emisijska tomografija/kompjutorizirana tomografija (SPECT/CT) somatostatinskih receptora u dijagnostici neuroendokrinih tumora", Medicina Fluminensis, vol. 57, no. 1, pp. 73-80, March 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:495948. [Accessed: 26 December 2024]

Metadata
Title (croatian)Hibridna jednofotonska emisijska tomografija/kompjutorizirana tomografija (SPECT/CT) somatostatinskih receptora u dijagnostici neuroendokrinih tumora
Title (english)Hybrid SPECT/CT Somatostatin Receptor Imaging of Neuroendocrine Tumours
AuthorMatej Maršić
AuthorTihana Klarica Gembić https://orcid.org/0000-0001-7209-6820
AuthorNeva Girotto
AuthorIvan Pribanić
AuthorTatjana Bogović Crnčić
AuthorSvjetlana Grbac-Ivanković
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Nuclear Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Nuclear Medicine
Abstract (croatian)
Cilj: Cilj rada bio je procijeniti doprinos jednofotonske emisijske tomografije / kompjutorizirane tomografije somatostatinskih receptora (SR SPECT/CT) s 99mTc-EDDA/HYNIC-Tyr3-oktreotidom (99mTc-Tektrotyd) u dijagnostici i procjeni proširenosti bolesti kod pacijenata oboljelih od neuroendokrinih tumora (NET-ova). Ispitanici i metode: Retrospektivno je analizirano 120 SR SPECT/CT snimanja pacijenata s patohistološki dokazanim NET-om s obzirom na vizualizaciju primarnih lezija i metastaza. U 45 pacijenata učinjena je i pozitronska emisijska tomografija 18F-fluorodeoksiglukozom (18F-FDG PET/CT) te su nalazi uspoređeni s nalazima SR SPECT/CT-a i vrijednostima kromogranina A. Rezultati: Od 120 pacijenata 47 (39 %) je na SR SPECT/CT upućeno nakon odstranjenja primarne lezije. Od preostala 73 pacijenta (61 %), u 56 (77 %) primarni je tumor bio vidljiv SR SPECT/CT-om, a u 9 (12 %) poznata lezija nije akumulirala radiofarmak. U 8 (11 %) pacijenata s NET-om nepoznatog primarnog sijela nalaz je bio negativan. Od 68 (57 %) pacijenta s dokazanim metastazama, u njih 57 (84 %) bile su vidljive SR SPECT/CT-om, a u 11 (16 %) nisu akumulirale radiofarmak. Od 45 (38 %) pacijenata kojima je učinjen i 18F-FDG PET/CT, u 27 (60 %) detekcija primarnih lezija i metastaza bila je sukladna nalazu SR SPECT/CT-a. Osjetljivost SR SPECT/CT-a bila je 77 % za primarne lezije i 84 % za metastaze, a 18F-FDG PET/CT-a 75 % za primarne lezije i 76 % za metastaze. Vrijednosti kromogranina A nisu pokazale statistički signifikantnu korelaciju s nalazima slikovne dijagnostike. Zaključci: SR SPECT/CT ima visoku osjetljivost za detekciju NET-ova. Osim toga, potvrđena je komplementarnost s 18F-FDG PET/CT-om te kod pacijenata s negativnim nalazom SR SPECT/CT-a treba učiniti 18F-FDG PET/CT i obrnuto.
Abstract (english)
The aim: The aim of this study was to evaluate the significance of somatostatin receptor single-photon emission computed tomography/computed tomography (SR SPECT/CT) with 99mTc-EDDA/HYNIC-Tyr3-octreotide (99mTc-Tektrotyd) in diagnostics and staging of patients with neuroendocrine tumours. Patients and methods: We retrospectively enrolled 120 patients with histologically proven NET who underwent SR SPECT/CT between January 2013 and February 2017. The patients’ data and SR SPECT/CT findings regarding primary lesion and metastases were analysed. In 45 patients, 2-deoxy-2-18F-fluoroglucose positron emission computed tomography/computed tomography (18F-FDG PET/CT) was performed, and the findings were compared to SR SPECT/CT and chromogranin A values. Results: Out of 120 patients, 47 (39%) underwent SR SPECT/CT after surgical removal of the primary lesion. In 73 (61%) remaining patients, the primary lesion was detected on SR SPECT/CT in 56 (77%), in 9 (12%) lesion did not accumulate 99mTc-Tektrotyd. SR SPECT/CT was negative in the remaining 8 (11%) patients with unknown primary. Out of 68 patients (57%) with metastases, 57 (84%) were detected on SR SPECT/CT, while 11 did not accumulate 99mTc- Tektrotyd. 18F-FDG PET/CT was performed in 45 patients, and findings were concordant with SR SPECT/CT in 27 (60%). The the sensitivity of SR SPECT/CT was 77% for primary lesions and 84% for metastases, and sensitivity of 18F-FDG PET/CT was 75% 76%, respectively. In 70 (58%) patients with available chromogranin A no statistically significant correlation was found with imaging methods. Conclusion: In patients with NET and negative SR SPECT/CT findings, 18F-FDG PET/CT should be recommended and vice versa, because of the complementarity of these procedures.
Keywords (croatian)
Keywords (english)
Languagecroatian
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleMedicina Fluminensis
Numberingvol. 57, no. 1, pp. 73-80
p-ISSN1847-6864
e-ISSN1848-820X
DOIhttps://doi.org/10.21860/medflum2021_365323
URN:NBNurn:nbn:hr:184:495948
Publication2021-03-01
Document URLhttps://hrcak.srce.hr/251264
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2021-03-03 18:28:11